MentalHealthDaily

Genetics & Depression: How Polygenic Risk Scores Predict Mood Over Long-Term (2024 Study)

by GLOOM

A recent study examined how our genetic makeup influences our temperament traits, particularly in relation to depression. By analyzing the polygenic risk for depression (PRS) and its correlation with various temperament traits over time, this research provides significant insights into the complex interplay between genetics and mood. Highlights: High PRS Linked to Increased Persistence: Individuals …

Combo of Neuroimaging, Transcriptome, Epigenetics to Understand Gray Matter Abnormalities in Major Depression (2024 Study)

by GLOOM

Major depressive disorder (MDD) affects millions worldwide, yet its underlying causes remain largely enigmatic. A new study integrated neuroimaging, transcriptomic, and epigenetic data to better understand the genetic underpinnings of MDD. This comprehensive approach revealed a complex interplay between brain structure, gene expression, and DNA methylation, offering new insights into this debilitating condition. Highlights: Integrative …

Probiotics & Synbiotics for the Metabolic Side Effects of Psychiatric Medications: Are They Effective? (2024 Review)

by GLOOM

Patients with severe mental illnesses (SMI), such as schizophrenia and chronic depression, often face the challenge of managing weight gain and metabolic complications, side effects commonly associated with antipsychotics and antidepressants. These medications are known to induce increased appetite and weight gain, leading to long-term metabolic syndromes. Recent studies have evaluated into the role of …

Biomarkers in Major Depression: Interleukin-33 (IL-33) & Mesencephalic Astrocyte-Derived Neurotrophic Factor (MANF) (2024 Study)

by GLOOM

Major depressive disorder (MDD) is a complex mental health condition that significantly impacts individuals’ lives globally. A recent study evaluates the biological underpinnings of this disorder, focusing on two specific biomarkers: interleukin-33 (IL-33) and mesencephalic astrocyte-derived neurotrophic factor (MANF). These findings could pave the way for new diagnostic and treatment strategies. Highlights: Major depressive disorder …

Aesthetic Chills to Treat Depression? Psychogenic Shivers, Frisson, Goosebumps (2024 Study)

by GLOOM

Depression, a prevalent mental health issue, often resists traditional treatments, making innovative approaches necessary. Recent research suggests that ‘aesthetic chills’—a peak emotional response accompanied by physical sensations like goosebumps—might offer significant benefits in treating depression. Highlights: Prevalence of Depression: Over 300 million people worldwide suffer from depression, making it a critical global health concern. Limitations …

Comparison of Brexipiprazole vs. Aripiprazole for Treatment-Resistant Depression (2024 Study)

by GLOOM

Antidepressant-resistant major depressive disorder (AR-MDD) poses significant challenges in psychiatric treatment. Antipsychotics like aripiprazole (ARI) and brexpiprazole (BRE) have emerged as effective adjunct therapies that may be more tolerable than older antipsychotics. Highlights: Both Brexipiprazole and Aripiprazole demonstrated better efficacy than placebo in treating AR-MDD in Japanese patients. Brexipiprazole showed a higher discontinuation rate due …

Analyzing Brain Connectivity with Advanced Neuroimaging to Treat Major Depression (2023 Research)

by GLOOM

Depression, a leading cause of disability globally, presents a myriad of treatment challenges. Recent advancements in neuroimaging, particularly in understanding brain connectivity, offer a new lens through which we can view and potentially enhance the treatment of Major Depressive Disorder (MDD). Highlights: Major Depressive Disorder (MDD) affects millions worldwide, with traditional treatments showing varied success …